{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-031743","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2022-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.573395+00:00","generated_at":"2026-06-21T05:56:51.823105+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"FDA approves new manufacturing site for Cumberland's Sancuso; $1M milestone due","bullets":["FDA approved Kindeva as new manufacturing and packaging site for Sancuso on Dec. 6, 2022.","Cumberland acquired U.S. rights to Sancuso in Jan. 2022; Kyowa Kirin led the FDA submission.","Cumberland will pay Kyowa Kirin a $1 million milestone payment following the approval.","Sancuso is the first FDA-approved transdermal patch for chemotherapy-induced nausea/vomiting."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-031743","json":"https://secwatch.observer/filing/0001628280-22-031743.json","markdown":"https://secwatch.observer/filing/0001628280-22-031743.md","text":"https://secwatch.observer/filing/0001628280-22-031743.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000162828022031743/0001628280-22-031743-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000162828022031743/cpix-20221206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T05:56:51.823105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}